New drug trial offers hope for stem cell transplant complications
NCT ID NCT04198922
Summary
This study is testing whether the drug acalabrutinib can help control chronic graft-versus-host disease in adults who have had a stem cell transplant. The trial involves 51 participants whose condition worsened despite steroid treatment. Patients take the medication orally for up to two years while researchers measure how well it controls their symptoms and improves their quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
Conditions
Explore the condition pages connected to this study.